Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4335 | Zinc Wiki | 0.35 |
| drug4251 | Vitamin D Wiki | 0.33 |
| drug4249 | Vitamin C Wiki | 0.27 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Adequate access to mental health is one of the most important problems facing the VA and VISN 19. Mental health patients who are stabilized and recovered should be transitioned back to primary care to increase availability in mental health for new patients, and to signal to recovered patients that they are successfully recovered. Because there are currently no methods to identify who is recovered or tools and processes to assist in transitions, few patients 'graduate' mental health. The FLOW program consists of an algorithm to identify patients who are potentially appropriate for transition, a user-friendly online report to communicate this information to providers, materials to explain this process to patients and providers, and an electronic medical record (EMR) note template to document the transition. The investigators are partnering with VISN 19 to evaluate this program using a stepped wedge design with 9 sites randomly allocated into 3 steps in the wedge. Sites will receive an evidence-based implementation facilitation approach. The investigators will evaluate the number of patients transitioned, success of those transitions, and patient and provider satisfaction.
Description: Percent of mental health patients in each of the participating clinics who are transitioned to primary care through use of the FLOW intervention, based upon electronic medical record data documenting this transition
Measure: Reach: Percent of specialty mental health patients transitioned to primary care Time: Change from baseline to 12 monthsDescription: Change in the VA publically reported metric "Percent of patients receiving an appointment within 7 days of the requested date" from baseline to 12 months
Measure: Effectiveness of intervention's impact on clinic access Time: Change from baseline to 12 monthsDescription: Percent of mental health providers who use the FLOW intervention for at least 1 patient, compared to the total number of mental health providers in the participating clinics
Measure: Adoption: Percent of mental health providers who use FLOW intervention Time: 12 monthsDescription: Percent if all FLOW components implemented as designed, based upon the items in the FLOW implementation checklist
Measure: Implementation fidelity to the protocol Time: 12 monthsDescription: Change in the VA publically reported metric "Percent of patients receiving an appointment within 7 days of the requested date" from 12 to 24 months
Measure: Maintenance of Effectiveness of intervention's impact on clinic access Time: 12-24 monthsDescription: Percent of all FLOW components implemented as designed, based upon the items in the FLOW implementation checklist, from 12 to 24 months
Measure: Maintenance of Implementation fidelity to the protocol Time: 12-24 monthsDescription: Percent of mental health providers who use the FLOW intervention for at least 1 patient, compared to the total number of mental health providers in the participating clinics, from 12-24 months
Measure: Maintenance of Adoption: percentage of mental health providers who use FLOW intervention Time: 12-24 monthsDescription: Percent of mental health patients in each of the participating clinics who are transitioned to primary care through use of the FLOW intervention, based upon electronic medical record data documenting this transition, during the maintenance period
Measure: Maintenance of Reach: percentage of specialty mental health patients transitioned to primary care Time: from 12-24 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports